Skip to main content

Table 3 Canonical pathways predicted by Ingenuity Pathway Analysis for significant genes differentially expressed in kidney cancer

From: Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia

Ingenuity canonical pathways -log (p-value) z-score Molecules
Wnt/β-catenin Signaling 0.271 2.530 CSNK1E,MYC,PPP2R4,TGFBR3,CD44,LEF1,SFRP1,UBC,CCND1,HNF1A,ACVR2A,LRP1
Synaptic Long Term Potentiation 0.481 −2.333 PLCB4,PPP1R1A,PPP1R3C,PPP3R1,PRKAR2A,CACNA1C,PLCL1,PLCD4,PRKCZ,PRKCA
NRF2-mediated Oxidative Stress Response 1.5 −2.333 GSTA3,AKR7A2,AKR7A3,GSTM1,GSTM3,NQO2,ABCC2,NQO1,DNAJC19,SOD1,PRKCZ,DNAJC11,AKR1A1,SCARB1,FMO1,GSTA1,AOX1,TXN,PRKCA,EPHX1
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 0.512 −2.324 PPARA,MAP3K15,APOE,APOM,PPP1R3C,PRKCZ,APOL1,ALB,PPP2R4,CYBA,APOC1,CHUK,APOD,RBP4,PRKCA
Sperm Motility 1.19 −2.309 PLA2G16,SLC16A10,PLCB4,PLA2R1,PRKAR2A,PNPLA3,PLCL1,PLA2G12B,PDE1A,PLCD4,PLA2G7,PRKCZ,PRKCA
Renin-Angiotensin Signaling 0.279 −2.121 ADCY9,GRB2,REN,PRKAR2A,CCL5,PRKCZ,AGT,PRKCA
Nitric Oxide Signaling in the Cardiovascular System 0.27 −1.890 KNG1,CAV1,PRKAR2A,CACNA1C,PDE1A,PRKCZ,PRKCA
Antioxidant Action of Vitamin C 3.01 1.897 PLA2G16,NAPEPLD,PLA2R1,SLC23A3,PLA2G7,GLRX,SLC2A3,PLCB4,SLC23A1,SLC2A2,PNPLA3,CHUK,TXN,PLA2G12B,PLCL1,PLCD4
Aldosterone Signaling in Epithelial Cells 1.34 −1.897 DNAJC12,DNAJC19,PDPK1,HSPD1,HSPA2,PRKCZ,HSPA12A,DNAJC11,PLCB4,SCNN1G,SLC12A1,CRYAA/LOC102724652,SCNN1B,PLCL1,PLCD4,PRKCA,AHCY
Valine Degradation I 10.11 NaN ECHS1,ABAT,ACADSB,BCKDHB,BCAT1,HIBCH,HIBADH,AUH,DLD,DBT,EHHADH,HADHA,ALDH6A1
Ethanol Degradation II 9.4 NaN HSD17B10,ADH6,ALDH1B1,ALDH4A1,ACSS1,ALDH9A1,ADH5,ALDH2,AKR1A1,ALDH3A2,ACSS2,ADHFE1,ACSL1,ALDH7A1,DHRS4
Fatty Acid β-oxidation I 9.4 NaN HSD17B10,ECHS1,SLC27A2,ACAA1,ACAA2,SCP2,ECI2,AUH,ACSL4,IVD,EHHADH,ACADM,HADHA,ACSL1,HADH
FXR/RXR Activation 9.17 NaN PPARA,KNG1,APOE,PKLR,APOH,ABCC2,SLC22A7,HNF1A,CYP8B1,MTTP,PCK2,SCARB1,SLC10A2,FGFR4,LPL,GC,AGT,APOM,SDC1,UGT2B4,CYP27A1,SERPINF2,APOL1,ALB,FABP6,APOC1,FBP1,G6PC,SLC51B,RBP4,APOD
Serotonin Degradation 8.46 NaN ADH6,HSD17B10,ALDH4A1,ALDH1B1,UGT3A1,UGT2B4,UGT2B7,UGT1A1,ALDH9A1,ADH5,ALDH2,AKR1A1,SMOX,ALDH3A2,ADHFE1,DHRS4,ALDH7A1,MAOA
Noradrenaline and Adrenaline Degradation 7.86 NaN ADH6,HSD17B10,ALDH4A1,ALDH1B1,ALDH9A1,ADH5,ALDH2,AKR1A1,SMOX,ALDH3A2,ADHFE1,DHRS4,ALDH7A1,MAOA
Tryptophan Degradation 7.34 NaN ALDH4A1,ALDH1B1,ALDH2,AKR1A1,SMOX,ALDH3A2,DDC,ALDH9A1,ALDH7A1,MAOA
PXR/RXR Activation 4.04 NaN PPARA,SCD,GSTM1,ABCB1,ABCC2,PRKAR2A,CES2,HMGCS2,UGT1A1,PCK2,ALDH3A2,GSTA1,G6PC,CYP2B6
Acute Myeloid Leukemia Signaling 0.491 0.816 RUNX1,MYC,GRB2,LEF1,CCND1,HNF1A,IDH1
Non-Small Cell Lung Cancer Signaling 0.481 −0.816 GRB2,PDPK1,EGF,ERBB2,CCND1,PRKCA
PTEN Signaling 0.662 0.905 FGFR3,GRB2,FGFR4,TGFBR3,PREX2,ITGA5,FGFR2,PDPK1,CHUK,CCND1,PRKCZ
Regulation of Cellular Mechanics by Calpain Protease 0.453 −1.000 GRB2,ITGA5,EGF,CCND1,ACTN1
ErbB2-ErbB3 Signaling 0.967 −1.890 MYC,GRB2,NRG3,PDPK1,ERBB3,ERBB2,CCND1
Aryl Hydrocarbon Receptor Signaling 2.07 NaN GSTA3,GSTM1,ALDH4A1,ALDH1B1,GSTM3,NQO2,NQO1,ALDH8A1,CCND1,ALDH9A1,MYC,ALDH1L1,ALDH1L2,ALDH3A2,GSTA1,ALDH5A1,ALDH6A1,ALDH7A1
HER-2 Signaling in Breast Cancer 1.01 NaN GRB2,PARD6B,EGF,ERBB3,ITGB8,ERBB2,CCND1,PRKCZ,PRKCA
Thyroid Cancer Signaling 0.828 NaN CXCL10,MYC,LEF1,CCND1,HNF1A
Endometrial Cancer Signaling 0.765 NaN MYC,GRB2,PDPK1,LEF1,ERBB2,CCND1
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 0.615 NaN CXCL8,FN1,IL1RL1,CXCL12,CCL5,HNF1A,CCND1,FCGR1A,PRKCZ,C5,MYC,PLCB4,F2RL1,PPP3R1,LEF1,CHUK,SFRP1,PLCL1,PLCD4,FCGR3A/FCGR3B,TNFSF13B,LRP1,PRKCA,ADAMTS4
Estrogen-mediated S-phase Entry 0.278 NaN MYC,CCND1
  1. *bold data shows presence and importance of CCND1 among identified canonical pathways